NCT01529541View on ClinicalTrials.gov

Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone

PHASE3CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

October 31, 2013

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Anagliptin

Anagliptin 100mg, tablet, twice a day (BID)

DRUG

Sitagliptin

Sitagliptin 100mg, tablet, once a day (QD)

Trial Locations (1)

Unknown

Kangbuk Samsung Hospital, Seoul

Sponsors

Lead Sponsor

JW Pharmaceutical

All Listed Sponsors

lead

JW Pharmaceutical

INDUSTRY